McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, et al. Progress in the management of malignant pleural mesothelioma in 2017. J Thorac Oncol. 2018;13:606–23.

Article  PubMed  PubMed Central  Google Scholar 

Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21(st) century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9:S28–S38.

Article  PubMed  PubMed Central  Google Scholar 

Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227:44–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.

Article  CAS  PubMed  Google Scholar 

Woods B, Paracha N, Scott DA, Thatcher N. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer. 2012;75:261–7.

Article  PubMed  Google Scholar 

Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375–86.

Article  CAS  PubMed  Google Scholar 

Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33:488–99.

Article  CAS  PubMed  Google Scholar 

Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18:792–802.

Article  PubMed  Google Scholar 

Carbone M, Yang H, Pass HI, Taioli E. Did the ban on asbestos reduce the incidence of mesothelioma? J Thorac Oncol. 2023;18:694–7.

Article  PubMed  Google Scholar 

Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA. 1995;92:10854–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994;54:5547–51.

CAS  PubMed  Google Scholar 

Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970–9.

Article  CAS  PubMed  Google Scholar 

Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8:1548.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010;465:243–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scheuermann JC, Gutierrez L, Muller J. Histone H2A monoubiquitination and Polycomb repression: the missing pieces of the puzzle. Fly. 2012;6:162–8.

Article  CAS  PubMed  Google Scholar 

Pasini D, Di Croce L. Emerging roles for Polycomb proteins in cancer. Curr Opin Genet Dev. 2016;36:50–8.

Article  CAS  PubMed  Google Scholar 

Piunti A, Shilatifard A. The roles of Polycomb repressive complexes in mammalian development and cancer. Nat Rev Mol Cell Biol. 2021;22:326–45.

Article  CAS  PubMed  Google Scholar 

LaFave LM, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21:1344–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Badhai J, Pandey GK, Song JY, Krijgsman O, Bhaskaran R, Chandrasekaran G, et al. Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice. J Exp Med. 2020;217:e20191257.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pandey GK, Landman N, Neikes HK, Hulsman D, Lieftink C, Beijersbergen R, et al. Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Cell Rep. Med. 2023;4:100915.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022;23:758–67.

Article  CAS  PubMed  Google Scholar 

Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. New Engl J Med. 2021;385:1207–18.

Article  CAS  PubMed  Google Scholar 

Oehl K, Vrugt B, Opitz I, Meerang M. Heterogeneity in malignant pleural mesothelioma. Int J Mol Sci. 2018;19:1603.

Article  PubMed  PubMed Central  Google Scholar 

Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, et al. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer. Breast Cancer Res. 2022;24:41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Casciello F, Kelly GM, Ramarao-Milne P, Kamal N, Stewart TA, Mukhopadhyay P, et al. Combined inhibition of G9a and EZH2 suppresses tumor growth via synergistic induction of IL24-mediated apoptosis. Cancer Res. 2022;82:1208–21.

Article  CAS  PubMed  Google Scholar 

Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, et al. Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. Nat Commun. 2018;9:2547.

Article  PubMed  PubMed Central  Google Scholar 

Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2015;520:239–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld JS, Iorio F, et al. Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition. Clin Cancer Res. 2017;24:84–94.

Article  PubMed  Google Scholar 

Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413–5.

Article  PubMed  PubMed Central  Google Scholar 

Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488–W93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bliss CI. The calculation of microbial assays. Bacteriol Rev. 1956;20:243–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guzman C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS ONEe. 2014;9:e92444.

Article  Google Scholar 

Ismail IH, Davidson R, Gagne JP, Xu ZZ, Poirier GG, Hendzel MJ. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 2014;74:4282–94.

Article  CAS  PubMed  Google Scholar